- Category: Pipeline
Pipeline
Eclipse reports positive phase 2 topline data on DME steroid implant
EC-104 demonstrated durability, consistent anatomical response, and a strong safety profile; company eyes pivotal program in 2027.
Pipeline
Stuart Therapeutics submits IND amendment for corneal wound healing
Planned proof-of-concept study is the first expansion beyond DED indication for ST-100 (vezocolmitide), with a phase 2 trial to follow in H2 2027.
Pipeline
EyePoint reports variable outcomes in latest phase 3 DURAVYU wet data readout
LUCIA trial fails to meet primary goal; company to cut workforce reduction by 53% as part of a strategic prioritization to advance phase 3 DME program.
Pipeline
Innovent's Sycume meets phase 3 endpoint for inactive TED
RESTORE-3 trial demonstrates efficacy in reducing proptosis and a favorable safety profile for patients with inactive TED.
Pipeline
Roche reports phase 3 data on steroid-free therapy for UME management
Company announces FDA acceptance of BLA submission as 52-week results find vamikibart demonstrated sustained improvements in vision.
Pipeline
FDA clears Surrozen's IND for DME therapy
First patient dosing in the DUET trial planned for later this year; study will be the first to evaluate humans treated with the bifunctional antibody.
Pipeline
Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation
Company reports a constructive meeting with the FDA over a planned trial evaluating oral tonabersat; currently eyeing a 2027 timeframe for kickoff.
Pipeline
4DMT advances DME gene therapy to phase 3 evaluations
Phase 3 4SIGHT trial has begun enrolling patients and 2-year phase 2 SPECTRA results show over 60% treatment burden reduction.
Pipeline
Aldeyra to formally appeal third reproxalap CRL
Company to submit a formal dispute resolution request following Type A and D meetings with FDA over the investigational DED drop.
Pipeline
Merck releases phase 2b/3 wet AMD data for tri-specific antibody
Topline data demonstrates non-inferiority and higher rates of two AEs and treatment discontinuation due to AEs.
Pipeline
Kodiak's tarcocimab meets wet AMD phase 3 endpoint, targets Q4 BLA
Zenkuda and KSI-501 both met the primary endpoint in DAYBREAK study, accelerating Kodiak’s development plans.
Pipeline
Beacon Therapeutics releases positive topline phase 2 data on laru-zova for XLRP
VISTA is reportedly the first pivotal trial in XLRP to achieve its FDA-endorsed primary endpoint; company plans to submit a rolling BLA later this year.
Pipeline
Sling Therapeutics raises $123M, begins phase 3 dosing for TED therapy
Following significant investment, Sling advances oral small molecule therapy to late-stage clinical trial testing.
Pipeline
Ocular Therapeutix reports positive pre-NDA FDA meeting for AXPAXLI
Company remains on track for a Q4 2026 submission; wet AMD IVT implant has the potential for long-term durability and fewer injections.
Pipeline
Opus Genetics releases positive phase 1/2 data in BEST1 retinal disease
Promising early results pave the way for a higher-dose cohort; FDA meeting signals potential phase 3 trial in 2027.Pipeline
Surrozen submits IND to FDA for DME therapeutic
Phase 1b/2a study to evaluate a bifunctional Wnt agonist and VEGF antagonist antibody that targets vascular leakage and promote retinal vascular integrity
Pipeline
FDA grants IDE approval to Ciliatech for glaucoma implant study
Clearance brings company closer to a clinical and regulatory pathway for the cilioscleral interpositioning device, designed to lower IOP in POAG.
Pipeline
FDA accepts Nanoscope's optogenetic gene therapy BLA for RP
The newly-renamed MOGENRY could become the first gene-agnostic treatment for patients with RP having severe vision loss.
Pipeline
Ocugen doses first patient in phase 3 GA gene therapy trial
OCU410 becomes third gene therapy from Ocugen to reach late-stage clinical trials; BLA filing is anticipated in 2028.
Pipeline